| Doxorubicin-formaldehyde conjugates targeting αvβ3 integrin DJ Burkhart, BT Kalet, MP Coleman, GC Post, TH Koch Molecular cancer therapeutics 3 (12), 1593-1604, 2004 | 107 | 2004 |
| Design, synthesis, and preliminary evaluation of doxazolidine carbamates as prodrugs activated by carboxylesterases DJ Burkhart, BL Barthel, GC Post, BT Kalet, JW Nafie, RK Shoemaker, ... Journal of medicinal chemistry 49 (24), 7002-7012, 2006 | 59 | 2006 |
| Doxazolidine induction of apoptosis by a topoisomerase II independent mechanism BT Kalet, MB McBryde, JM Espinosa, TH Koch Journal of medicinal chemistry 50 (18), 4493-4500, 2007 | 29 | 2007 |
| Transcription factor Ets1 cooperates with estrogen receptor α to stimulate estradiol-dependent growth in breast cancer cells and tumors BT Kalet, SR Anglin, A Handschy, LE O’Donoghue, C Halsey, L Chubb, ... PloS one 8 (7), e68815, 2013 | 26 | 2013 |
| Anthracycline–Formaldehyde Conjugates and Their Targeted Prodrugs TH Koch, BL Barthel, BT Kalet, DL Rudnicki, GC Post, DJ Burkhart Anthracycline Chemistry and Biology II: Mode of action, clinical aspects and …, 2008 | 23 | 2008 |
| Antiestrogen binding site and estrogen receptor mediate uptake and distribution of 4-hydroxytamoxifen-targeted doxorubicin− formaldehyde conjugate in breast cancer cells PJ Burke, BT Kalet, TH Koch Journal of medicinal chemistry 47 (26), 6509-6518, 2004 | 23 | 2004 |
| Methods of treating cancer with doxazolidine and prodrugs thereof TH Koch, DJ Burkhart, GC Post, JW Nafie, BT Kalet, BL Barthel, ... US Patent 8,404,650, 2013 | 9 | 2013 |
| Targeted Drug-Formaldehyde Conjugates and Methods of Making and Using the Same T Koch, M Coleman, P Cogan, P Burke, G Post, D Burkhart, A McKenzie, ... US Patent App. 10/570,471, 2007 | 2 | 2007 |
| IGF2 mRNA binding protein 1 drives growth, metastasis and chemoresistance in osteosarcoma. BT Kalet, LE O'Donoghue, DL Duval Cancer Research 73 (8_Supplement), 3008-3008, 2013 | 1 | 2013 |
| Defining the Significance of Insulin‐like Growth Factor 2 mRNA‐Binding Protein 1 (IGF2BP1) Expression in both Human and Canine Osteosarcoma NM Alyami, BT Kalet, L Pfaff, S Peck, DL Duval The FASEB Journal 33 (S1), 815.8-815.8, 2019 | | 2019 |
| Insulin-like growth factor 2 mRNA binding protein 1 (IGF2BP1) drives growth, metastasis and chemoresistance in human and canine osteosarcoma LE Pfaff, BT Kalet, DD Dailey, DL Duval MOLECULAR CANCER RESEARCH 12, 2014 | | 2014 |
| Abstract A23: Insulin-like growth factor 2 mRNA binding protein 1 (IGF2BP1) drives growth, metastasis and chemoresistance in human and canine osteosarcoma LE Pfaff, BT Kalet, DD Dailey, DL Duval Molecular Cancer Research 12 (11_Supplement), A23-A23, 2014 | | 2014 |
| Doxorubicin and its formaldehyde conjugates BT Kalet University of Colorado at Boulder, 2007 | | 2007 |
| The conjugation of doxaliform to alpha (nu) beta3 (alpha (nu) beta (3)) targeting peptides provides a potential therapeutic alternative for the management of alpha (nu) beta (3 … L Vellon, JA Menendez, DJ Burkhart, BT Kalet, TH Koch, R Lupu BREAST CANCER RESEARCH AND TREATMENT 94, S71-S72, 2005 | | 2005 |
| Biological Evaluation of Doxorubicin-formaldehyde Conjugates Targeted to the [alpha] v [beta] 3 Integrin, Estrogen Receptor and Antiestrogen Binding Site BT Kalet University of Colorado, 2004 | | 2004 |
Javier A. Menéndez (ORCID:0000-000...Catalan Institute of Oncology (ROR 01j1eb875)Email verificata su idibgi.org
